| Summary of Carrying Amounts of Goodwill |
The changes in the carrying amounts of goodwill for the laboratory services segment and the therapeutic development segment in the six months ended June 30, 2026 were as follows:
|
|
|
|
|
|
|
|
|
Laboratory Services |
|
|
Therapeutic Development |
|
|
(in thousands) |
|
Balance at December 31, 2025 |
$ |
— |
|
|
$ |
25,080 |
|
Acquisition |
|
31,379 |
|
|
|
— |
|
Measurement period adjustment |
|
130 |
|
|
|
(2,728 |
) |
Balance at June 30, 2026 |
$ |
31,509 |
|
|
$ |
22,352 |
|
|
| Summaries of Goodwill and Acquisitions-Related Intangibles Balances |
Summaries of intangible assets balances as of June 30, 2026, and December 31, 2025, were as follows:
|
|
|
|
|
|
|
|
|
|
Weighted-Average Amortization Period |
June 30, 2026 |
|
|
December 31, 2025 |
|
|
|
(in thousands) |
|
Laboratory Services |
|
|
|
|
|
|
Customer relationships |
12 Years |
$ |
105,170 |
|
|
$ |
83,135 |
|
Less: accumulated amortization |
|
|
(29,439 |
) |
|
|
(25,633 |
) |
Customer relationships, net |
|
|
75,731 |
|
|
|
57,502 |
|
|
|
|
|
|
|
|
Royalty-free technology |
10 Years |
|
5,453 |
|
|
|
5,291 |
|
Less: accumulated amortization |
|
|
(2,818 |
) |
|
|
(2,469 |
) |
Royalty-free technology, net |
|
|
2,635 |
|
|
|
2,822 |
|
|
|
|
|
|
|
|
Trade name |
7 Years |
|
4,490 |
|
|
|
3,790 |
|
Less: accumulated amortization |
|
|
(2,201 |
) |
|
|
(1,896 |
) |
Trade name, net |
|
|
2,289 |
|
|
|
1,894 |
|
|
|
|
|
|
|
|
Laboratory information system platform |
5 Years |
|
1,860 |
|
|
|
1,860 |
|
Less: accumulated amortization |
|
|
(1,829 |
) |
|
|
(1,643 |
) |
Laboratory information system platform, net |
|
|
31 |
|
|
|
217 |
|
|
|
|
|
|
|
|
In-place lease intangible assets |
5 Years |
|
360 |
|
|
|
360 |
|
Less: accumulated amortization |
|
|
(290 |
) |
|
|
(255 |
) |
In-place lease intangible assets, net |
|
|
70 |
|
|
|
105 |
|
|
|
|
|
|
|
|
Purchased patent |
10 Years |
|
29 |
|
|
|
29 |
|
Less: accumulated amortization |
|
|
(16 |
) |
|
|
(14 |
) |
Purchased patent, net |
|
|
13 |
|
|
|
15 |
|
Total |
|
|
80,769 |
|
|
|
62,555 |
|
|
|
|
|
|
|
|
Therapeutic Development |
|
|
|
|
|
|
Customer relationships |
18 Years |
|
2,300 |
|
|
|
2,300 |
|
Less: accumulated amortization |
|
|
(128 |
) |
|
|
(64 |
) |
Less: accumulated impairment |
|
|
(2,172 |
) |
|
|
— |
|
Customer relationships, net |
|
|
— |
|
|
|
2,236 |
|
|
|
|
|
|
|
|
In-process research & development |
n/a |
|
68,490 |
|
|
|
68,490 |
|
Total |
|
|
68,490 |
|
|
|
70,726 |
|
Total intangible assets, net |
|
$ |
149,259 |
|
|
$ |
133,281 |
|
|
| Summary of Annual Amortization Expense For Acquisition-Related Intangibles |
Based on the carrying value of intangible assets recorded as of June 30, 2026, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for intangible assets is expected to be as follows:
|
|
|
|
|
Amounts |
|
|
(in thousands) |
|
Year ending December 31, |
|
|
2026 (remaining 6 months) |
$ |
4,949 |
|
2027 |
|
9,667 |
|
2028 |
|
9,633 |
|
2029 |
|
9,200 |
|
2030 |
|
9,014 |
|
2031 |
|
8,602 |
|
Thereafter |
|
29,704 |
|
Total |
$ |
80,769 |
|
|